David Walsey, ext. The objective of the multi-dose Phase I study is to determine nasal absorption, tolerance, and safety of this agent in healthy volunteers. The Company's intranasal formulation seeks to offer an alternate dosage form providing rapid onset of action of migraine pain relief and reduced adverse events, such as episodes of nausea and vomiting, as compared to oral dosage forms. By using Formulation Science, we intend to fill the need for faster acting pain relief while providing a more favorable side effect profile for the betterment of migraine sufferers. It is estimated that more than 23 million people in the U.S. alone suffer from migraine, which can severely limit a migraine sufferer's ability to function in normal daily routines.
Attacks occur periodically, and can last from a few hours to several days.
These changes may be caused by alterations in serotonin, a naturally occurring neurotransmitter. Serotonin affects nerve cells by stimulating and interacting with certain receptors, which in turn trigger certain responses in the cells. Triptans mimic certain actions of serotonin by activating specific 5-HT receptors that constrict blood vessels that may be dilated and distended during a migraine attack. Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using Formulation Science, a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, to provide new therapeutic options. Nastech Safe Harbor Statement Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties.